Asset Acquisition, Contingent Consideration, Current

No definition available.

Name:	dare_AssetAcquisitionContingentConsiderationCurrent
Namespace Prefix:	dare_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Maximum Potential Milestone Payments

+ References

No definition available.

+ Details

Name:	dare_MaximumPotentialMilestonePayments
Namespace Prefix:	dare_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Milestone payments, contingent amount.

+ References

No definition available.

+ Details

Name:	dare_MilestonePaymentsContingentAmount
Namespace Prefix:	dare_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Milestone Payments, Contingent Amount, First Commercial Sale Amount

+ References

No definition available.

+ Details

Name:	dare_MilestonePaymentsContingentAmountFirstCommercialSaleAmount
Namespace Prefix:	dare_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Milestone Payments, Contingent Amount, Sales Based Milestones Amount

+ References

No definition available.

+ Details

Name:	dare_MilestonePaymentsContingentAmountSalesBasedMilestonesAmount
Namespace Prefix:	dare_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Milestone Payments, Reimburse Amount, PDUFA Fees and Other Manufacturing Expenses

+ References

No definition available.

+ Details

Name:	dare_MilestonePaymentsReimburseAmountPDUFAFeesAndOtherManufacturingExpenses
Namespace Prefix:	dare_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Payment of Additional Consideration in Business Combination

+ References

No definition available.

+ Details

Name:	dare_PaymentOfAdditionalConsiderationInBusinessCombination
Namespace Prefix:	dare_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Payments to Stockholders' Representative in Business Combination

+ References

No definition available.

+ Details

Name:	dare_PaymentsToStockholdersRepresentativeInBusinessCombination
Namespace Prefix:	dare_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Potential Annual License Maintenance Fee Payments, Thereafter

+ References

No definition available.

+ Details

Name:	dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter
Namespace Prefix:	dare_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Research and development milestone payment.

+ References

No definition available.

+ Details

Name:	dare_ResearchAndDevelopmentMilestonePayment
Namespace Prefix:	dare_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Percentage of royalty rate.

+ References

No definition available.

+ Details

Name:	dare_RoyaltyRatePercentage
Namespace Prefix:	dare_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Upfront License Fee, Advanced Written Notice, Period

+ References

No definition available.

+ Details

Name:	dare_UpfrontLicenseFeeAdvancedWrittenNoticePeriod
Namespace Prefix:	dare_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Upfront License Fee, Amount Paid

+ References

No definition available.

+ Details

Name:	dare_UpfrontLicenseFeeAmountPaid
Namespace Prefix:	dare_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

Strategic Agreements (Details) - USD ($)		1 Months Ended									3 Months Ended	12 Months Ended
Strategic Agreements (Details) - USD ($)	Dec. 02, 2025	Jul. 31, 2023	Aug. 31, 2022	Jul. 31, 2022	Jan. 31, 2020	Nov. 30, 2019	May 31, 2018	Apr. 30, 2018	Feb. 28, 2018	Mar. 31, 2017	Dec. 31, 2023	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Aug. 31, 2023
Upon Achievement Of Specified Development And Regulatory Milestones \| Related Party
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payments, contingent amount												$ 50,000,000.0
Microchips Biotech, Inc.
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payment of additional consideration in business combination												0				$ 1,250,000
Microchips Biotech, Inc. \| Upon Achievement Of Specified Development And Regulatory Milestones
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payments						$ 46,500,000
Asset acquisition, contingent consideration, current						$ 55,000,000.0
ADVA Tec Agreement \| Upon Achievement Of Specified Development And Regulatory Milestones
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payments										$ 14,600,000
ADVA Tec Agreement \| Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of royalty rate										10.00%
ADVA Tec Agreement \| Minimum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of royalty rate										1.00%
Douglas License Agreement \| Upon Achieving Certain Development Milestones
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Sales based milestones amount																		$ 5,250,000
Douglas License Agreement \| Upon Achieving Certain Commercial Milestones
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Sales based milestones amount																		$ 64,000,000.0
Hennepin License Agreement \| Clinical And Regulatory Milestones
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Maximum potential milestone payments			$ 6,250,000
Hennepin License Agreement \| Sales Milestones
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Maximum potential milestone payments			$ 45,000,000.0
Licensing Agreements \| Related Party
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payments, contingent amount												1,000,000.0
Licensing Agreements \| ADVA Tec Agreement \| Upon Reaching Certain Worldwide Net Sales Milestones
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payments										$ 20,000,000.0
Licensing Agreements \| Upon Achieving Certain Development Milestones \| Maximum \| Related Party
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payments, contingent amount											$ 500,000					300,000
Licensing Agreements \| Upon Achieving Certain Commercial Milestones \| Related Party
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payments, contingent amount												850,000
Licensing Agreements \| Upon Achieving Certain Commercial Milestones \| Upon Achievement Of Specified Development And Regulatory Milestones \| Related Party
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payments, contingent amount												1,200,000
Licensing Agreements \| Licensed Product or Process for Vaginal or Urological Use \| Related Party
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payments, contingent amount												250,000
Assignment Agreement \| Upon Achieving Certain Clinical And Regulatory Development Milestones \| Related Party
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payments, contingent amount												1,100,000
Merger Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Maximum potential milestone payments							$ 15,500,000
Milestone payments							3,200,000
Pear Tree Pharmaceuticals, Inc. \| Sales Milestones
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Maximum potential milestone payments							$ 47,000,000.0
Juniper Pharmaceuticals, Inc.
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront license fee paid								$ 250,000
Potential annual license maintenance fee payments, thereafter								100,000
Juniper Pharmaceuticals, Inc. \| Clinical And Regulatory Milestones
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Maximum potential milestone payments								13,500,000
Juniper Pharmaceuticals, Inc. \| Sales Milestones
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Maximum potential milestone payments								$ 30,300,000
License And Collaboration Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payments, contingent amount									$ 18,000,000.0
License And Collaboration Agreement \| Upon Achieving Certain Commercial Milestones
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payments, contingent amount									$ 100,000,000.0			1,000,000.0
Organon
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront license fee paid				$ 10,000,000.0								12,800,000			$ 10,000,000.0
Sales based milestones amount												$ 180,000,000.0
Reimburse amount, PDUFA fees and other manufacturing expenses		$ 1,000,000.0												$ 1,000,000.0
Milestone payments, contingent amount, first commercial sale amount														$ 1,800,000
Advanced written notice period												120 days
Bayer \| Collaborative Arrangement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront license fee paid	$ 1,000,000.0												$ 1,000,000.0				$ 1,000,000.0
Bayer \| Royalty Revenue \| Collaborative Arrangement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront license fee paid					$ 1,000,000.0
Former Stockholders of MBI \| Microchips Biotech, Inc.
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payments to stockholders' representative in business combination																$ 75,000
Catalent and MilanaPharm \| Licensing Agreements
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payments, contingent amount												$ 1,000,000.0